Gossamer Bio stock falls 5.99 percent after FDA filing
Published on 09/24/2026 at 13:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gossamer Bio stock stood at USD 10.99 on Nasdaq on September 23, 2026, down 5.99 percent. The clinical-stage biotechnology company submitted its first New Drug Application for seralutinib to the FDA on September 23, according to Business Wire.
FDA filing reaches a key gate
The application seeks approval for seralutinib in pulmonary arterial hypertension. The submission is supported by the Phase 3 PROSERA study, the Phase 2 TORREY study and additional analyses, giving the company a regulatory milestone after years of clinical development.
Business Wire reported that the FDA characterized the statistical significance and treatment effect from PROSERA as review issues rather than filing issues during a June 2026 pre-NDA meeting. The agency is expected to decide whether to accept the application for filing later in 2026.
Revenue and cash set the frame
Gossamer reported USD 9.2 million of second-quarter 2026 revenue from its Chiesi collaboration, down from USD 11.5 million in the year-earlier quarter. Research and development expense fell to USD 26.4 million from USD 41.6 million, according to Stock Titan.
Cash, cash equivalents and marketable securities totaled USD 57.0 million on June 30, 2026. The same report said Gossamer expects that liquidity to fund operations into the first quarter of 2027, while a debt exchange reduced principal by USD 115.9 million.
Stock trades near its yearly low
The USD 10.99 reference price on September 23, 2026, was USD 1.87 above the 52-week low of USD 9.12 and USD 298.61 below the 52-week high of USD 309.60. Market capitalization was USD 67,155,318, making the FDA filing the companys most immediate valuation event while investors weigh regulatory progress against financing needs.
Gossamer Bio stock facts
- Company: Gossamer Bio, Inc.
- Ticker: GOSS
- Trading venue: Nasdaq Global Select Market
- Price as of September 23, 2026: USD 10.99
- Market capitalization: USD 67,155,318 (as of September 23, 2026)
- 52-week range: USD 9.12-309.60 (as of September 23, 2026)
- Sector / Industry: Healthcare / Biotechnology
